Actos Bladder Cancer Risk Shown in May 31, 2012 Study

Actos bladder cancer risks shown in May 31, 2012 study, establishes Actos bladder cancer risk.

Actos, the trade name for the diabetes drug Pioglitazone, is associated with an increased risk of bladder cancer, finds a study pub

lished on today.

The results show that more than two years daily exposure to pioglitazone doubles the risk of Actos bladder cancer.

Actos bladder cancer risks were evaluated in a new study reported in on May 31, 2012. The study confirms previous studies

showing an Actos bladder cancer risk. According to an excerpt from the article, the Actos bladder cancer risk is clearly established:

Use of the anti-diabetic agent pioglitazone (Actos) is associated with an increased risk of bladder cancer, a nested case-control study confirmed.

Patients with type 2 diabetes who were ever treated with pioglitazone [Actos] had an 83% higher risk for bladder cancer (adjusted rate ratio 1.83, 95% CI 1.10 to 3.05) than those who had never used the thiazolidinedione, according to Laurent Azoulay, PhD, of McGill University in Montreal, and colleagues.

This was a drug-specific effect, because patients taking rosiglitazone (Avandia) did not have an elevated risk (RR 1.14, 95% CI 0.78 to 1.68), the

researchers reported online in


The results of this analysis differed from those of a study being presented this week at the annual meeting of the American Society of Clinical Oncology, which suggested that the bladder cancer risk was a class effect for glitazones.

Other previous efforts to ascertain if pioglitazone [Actos] is associated with bladder cancer have had conflicting results, but the FDA and the Canadian health authorities have added a warning of that risk to the drug’s labeling, and some European countries have restricted its use.

(Emphasis added)

In other articles published today about the study, ScienceCodex reported that the new study shows that 2 years of treatment with Actos doubles the risk of bladder cancer.

(Emphasis added).

Actos Bladder Cancer Resources May 31, 2012:

Actos (pioglitazone): Popular Diabetes Drug Has Potential to Increase Risk of Bladder Cancer

Evidence is building that the use of the diabetes medication Actos (pioglitazone) may be associated with an increased risk of bladder cancer. Actos is a diabetes medication that is manufactured by Takeda Pharmaceuticals, and it is prescribed by doct

ors in accordance with an overall program that includes a healthy diet and a regiment of exercise in an viagra price effort to control the symptoms and problems

associated with type 2 diabetes. To date, Actos remains available on the American market.

Unfortunately, reports of Actos side effects that included the development of bladder cancer led to the medication being pulled from the market in France in June of 2011 and to the United States Food and Drug Administration to approve new Actos cancer warnings for patients in August of 2011.

Health Canada issued a warning on April 19, 2012 that the diabetes drug Actos may cause an increased risk of bladder cancer. Authorities there also stated they had come to an agreement with Takeda Pharmaceuticals, maker of the drug, to add a label warning addressing the risk.

An FDA Safety Alert reported the agency is aware of a

recent epidemiological study conducted in France which suggests an increased risk of bladder cancer with pioglitazone. Based on the results of this study, France has suspended the use of pioglitazone and Germany has recommended not to start pioglitazone in new patients.